Search

A recent study conducted at the University of Eastern Finland explored the potential of boronated tryptophans as boron delivery agents for Boron Neutron Capture Therapy (BNCT) in cancer treatment. The researchers synthesized both enantiomers of 5- and 6-boronotryptophans and evaluated their uptake in human cancer cell lines, finding differences in boron compound accumulation between the cell lines. The study suggests that tryptophan derivatives could be effective boron carriers in cases where the clinically used boron carrier, l-BPA, is ineffective. The research has been peer-reviewed and offers valuable insights into potential advancements in cancer therapy. [Extracted from the article]